Core Viewpoint - Illumina, Inc. has appointed Everett Cunningham as Chief Commercial Officer, effective June 10, 2024, to enhance its global commercial organization and drive growth in the healthcare sector [1][2]. Group 1: Appointment Details - Everett Cunningham will be responsible for building, guiding, and managing Illumina's global commercial organization [2]. - Cunningham has over 20 years of commercial leadership experience in healthcare technology, life sciences, and pharmaceuticals [1][2]. - He previously served as Chief Commercial Officer at Exact Sciences, overseeing marketing, sales, and customer service functions [2]. Group 2: Leadership Experience - Prior to his role at Exact Sciences, Cunningham held senior leadership positions at Quest Diagnostics, GE Healthcare, and Pfizer, where he spent 21 years [2]. - He has a proven track record in driving operational excellence, delivering top-line results, and expanding into new markets [2]. Group 3: Company Vision - Illumina's CEO, Jacob Thaysen, expressed enthusiasm for Cunningham's appointment, highlighting his experience and passion for addressing significant healthcare challenges [2]. - The company aims to leverage Cunningham's leadership to capitalize on its position in next-generation sequencing and meet customer needs [2].

Illumina, Inc. (NASDAQ:ILMN) Bernstein Strategic Decisions Conference May 29, 2024 9:00 AM ET Company Participants Ankur Dhingra - Chief Financial Officer Salli Schwartz - Vice President, Investor Relations Conference Call Participants Eve Burstein - Bernstein Research Eve Burstein Thanks so much for joining us. My name is Eve Burstein. I cover US life science, tools and diagnostics here at Bernstein. And I'm delighted to be joined by our Illumina friends. So Ankur Dhingra, CFO, Salli Schwartz, Head of IR. ...

Studies presented represent key focus areas, including building evidence for clinical utility of comprehensive genomic profiling; overcoming market access barriers, and progressing the whole-genome approach for MRDSAN DIEGO, May 29, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced some of its latest research being presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 31–June 4 in Chicago. Highlights ...

SAN DIEGO, May 28, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today published its fifth annual Corporate Social Responsibility (CSR) Report. The report highlights the company's ongoing commitments and progress made in 2023 toward advancing human health by serving as a champion for patients, communities, employees, and the planet.Illumina released its 2023 CSR Report today, highlighting the company’s ongoing commitments and progress made ...

Ms. Richo brings more than 30 years of regulated-industry experience as an attorney and legal executive, with extensive experience in compliance and business ethics, intellectual property, and corporate litigation. She formerly served as Corporate Senior Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary at Cargill, where she oversaw the company's corporate governance, global ethics and compliance, global security, global government relations, law, and shareholder relations f ...

SAN DIEGO, May 15, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference:Bernstein's 40th Annual Strategic Decisions Conference on May 29, 2024Fireside chat at 6:00am Pacific Time (9:00am Eastern Time)The webcast can be accessed through the Investor Info section of Illumina's website at investor.illumina.com. A replay will be posted on Illumina's website after the event and will be available for at least 30 days following ...

Summary of Illumina, Inc. Conference Call Company Overview - **Company**: Illumina, Inc. (NASDAQ:ILMN) - **Event**: RBC Capital Markets Global Healthcare Call - **Date**: May 14, 2024 Key Points Leadership Transition - Ankur Dhingra, the new CFO, has extensive experience in the life sciences industry, previously serving at Agilent Technologies and in molecular diagnostics [2][3] Financial Guidance and Performance - Dhingra was involved in the earnings process and guidance development shortly after joining [5] - Q1 results showed a revenue beat driven by consumables and backlog build, with gross margins expanding by 190 basis points [7][13] - The company maintained its full-year guidance, citing stable market conditions and a prudent approach to risk management [15] Operational Excellence - Illumina is focusing on operational excellence, with opportunities identified across all lines of P&L, including gross margin, R&D, and SG&A [7] - The executive leadership team is aligned and energized towards key priorities, leading to a reduction in operating expenses year-over-year [7] Revenue Segmentation and Reporting - There is an intent to provide detailed metrics to help investors understand business drivers better, with a focus on clinical versus research revenue [9][10] - Clinical sequencing consumables revenue increased by high single digits in Q1, with 35% of shipments going to clinical customers [11] Pricing Dynamics - Annual price increases were successfully realized, contributing positively to revenue despite competitive pressures [17] - Transition to new high-throughput instruments is expected to drive sequencing growth, with a projected 35% increase in sequencing throughput [18] R&D Investment - Historically, Illumina has invested around 20% of sales in R&D, which is seen as necessary for maintaining innovation and market leadership [28] - Dhingra emphasized the importance of justifying R&D expenditures with good returns, while also exploring cost efficiencies [29] Market Outlook - The company is optimistic about returning to higher growth rates, supported by strong demand for sequencing and new product launches [33] - Discussions with customers indicate significant anticipated capacity needs, suggesting a positive outlook for future growth [33] GRAIL Update - Illumina is exploring both a potential sale and a spin-off of GRAIL, with a maximum capital outlay of approximately $1 billion required for the spin-off [36] - The European Commission fine is currently on appeal, with a decision expected in 2025 or 2026 [37] Additional Insights - The company is actively working on strategies to enhance innovation while managing costs effectively [29] - There is a strong focus on customer engagement to facilitate the adoption of new technologies and products [27] This summary captures the essential insights from the conference call, highlighting Illumina's strategic direction, financial performance, and market outlook.

GRAIL to host Capital Markets Day on May 13, 2024  SAN DIEGO, May 6, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that it has publicly filed a Form 10 registration statement with the U.S. Securities and Exchange Commission ("SEC"), in connection with its intended divestiture of GRAIL. A version of this registration statement was submitted to the SEC last December as required. The Form 10 includes detailed information about GRAIL, including historic financial information, a description ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended March 31, 2024 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-35406 Illumina, Inc. (Exact name of registrant as specified in its charter) Delaware 33-0804655 (State or other jurisdiction of incorporation ...

SAN DIEGO, May 3, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: RBC 2024 Global Healthcare Conference on May 14, 2024Fireside chat at 5:30am Pacific Time (8:30am Eastern Time) The webcast can be accessed through the Investor Info section of Illumina's website at investor.illumina.com. A replay will be posted on Illumina's website after the event and will be available for at least 30 days following. About Illumi ...